Apellis Pharmaceuticals Management
Management criteria checks 3/4
Apellis Pharmaceuticals' CEO is Cedric Francois, appointed in Sep 2009, has a tenure of 14.67 years. total yearly compensation is $10.37M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 1.51% of the company’s shares, worth $75.77M. The average tenure of the management team and the board of directors is 5.3 years and 8.8 years respectively.
Key information
Cedric Francois
Chief executive officer
US$10.4m
Total compensation
| CEO salary percentage | 7.1% |
| CEO tenure | 14.7yrs |
| CEO ownership | 1.5% |
| Management average tenure | 5.3yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09
Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For
Jul 19Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week
May 13Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?
Apr 18Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?
Dec 14Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates
Nov 09Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise
Sep 28Apellis gains as FDA says AdCom unnecessary for eye disease candidate
Sep 07Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Aug 17Apellis to exchange $75.6M in convertible senior notes for common stock
Jul 27Apellis stock soars 24% as FDA grants priority review to pegcetacoplan for eye disorder
Jul 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$417m |
| Dec 31 2023 | US$10m | US$735k | -US$529m |
| Sep 30 2023 | n/a | n/a | -US$606m |
| Jun 30 2023 | n/a | n/a | -US$657m |
| Mar 31 2023 | n/a | n/a | -US$691m |
| Dec 31 2022 | US$9m | US$681k | -US$652m |
| Sep 30 2022 | n/a | n/a | -US$634m |
| Jun 30 2022 | n/a | n/a | -US$638m |
| Mar 31 2022 | n/a | n/a | -US$702m |
| Dec 31 2021 | US$9m | US$647k | -US$746m |
| Sep 30 2021 | n/a | n/a | -US$520m |
| Jun 30 2021 | n/a | n/a | -US$460m |
| Mar 31 2021 | n/a | n/a | -US$360m |
| Dec 31 2020 | US$9m | US$619k | -US$345m |
| Sep 30 2020 | n/a | n/a | -US$536m |
| Jun 30 2020 | n/a | n/a | -US$470m |
| Mar 31 2020 | n/a | n/a | -US$423m |
| Dec 31 2019 | US$4m | US$560k | -US$305m |
| Sep 30 2019 | n/a | n/a | -US$228m |
| Jun 30 2019 | n/a | n/a | -US$194m |
| Mar 31 2019 | n/a | n/a | -US$156m |
| Dec 31 2018 | US$4m | US$550k | -US$128m |
| Sep 30 2018 | n/a | n/a | -US$109m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$64m |
| Dec 31 2017 | US$2m | US$400k | -US$51m |
Compensation vs Market: Cedric's total compensation ($USD10.37M) is about average for companies of similar size in the US market ($USD8.44M).
Compensation vs Earnings: Cedric's compensation has increased whilst the company is unprofitable.
CEO
Cedric Francois (51 yo)
14.7yrs
Tenure
US$10,373,049
Compensation
Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.7yrs | US$10.37m | 1.51% $ 75.8m | |
| Co-Founder & Director | 15.3yrs | US$495.96k | 0.64% $ 32.0m | |
| CFO & Treasurer | 6.6yrs | US$3.74m | 0.084% $ 4.2m | |
| Chief Operating Officer | less than a year | US$3.71m | 0.023% $ 1.2m | |
| General Counsel | 10.3yrs | US$4.89m | 0.094% $ 4.7m | |
| Chief Medical Officer | 1.3yrs | US$4.43m | 0.0052% $ 259.2k | |
| Co-Founder & Chief Scientific Officer | 14.7yrs | US$3.08m | 0.90% $ 45.0m | |
| VP, Corporate Controller & Chief Accounting Officer | 2.8yrs | no data | 0.0085% $ 426.7k | |
| Senior Vice President | no data | no data | no data | |
| Chief People Officer | 4yrs | no data | 0.00073% $ 36.6k | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 2yrs | no data | no data | |
| Senior Vice President | 5.3yrs | no data | 0.0031% $ 155.4k |
5.3yrs
Average Tenure
50.5yo
Average Age
Experienced Management: APLS's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.7yrs | US$10.37m | 1.51% $ 75.8m | |
| Co-Founder & Director | 14.7yrs | US$495.96k | 0.64% $ 32.0m | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 8.8yrs | no data | no data | |
| Independent Chairman of the Board | 10.8yrs | US$504.08k | 0.00056% $ 28.1k | |
| Independent Director | 10.8yrs | US$488.46k | 0.00056% $ 28.1k | |
| Member of AMD Scientific Advisory Board | 8.8yrs | no data | no data | |
| Member of PNH Scientific Advisory Board | 8.8yrs | no data | no data | |
| Member of Pulmonology Scientific Advisory Board | 8.8yrs | no data | no data | |
| Independent Director | 4.1yrs | US$489.08k | 0.0047% $ 234.6k | |
| Independent Director | 14.2yrs | US$480.96k | 0.11% $ 5.4m | |
| Member of Pulmonology Scientific Advisory Board | no data | no data | no data | |
| Member of Pulmonology Scientific Advisory Board | 8.8yrs | no data | no data |
8.8yrs
Average Tenure
56.5yo
Average Age
Experienced Board: APLS's board of directors are considered experienced (8.8 years average tenure).